<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2011-03-14 07:22:47Immunosuppressants Monoclonal antibodies Disease-modifying antirheumatic drug Rheumatoid arthritis TNF inhibitor Infliximab Rheumatology Etanercept Adalimumab Arthritis Tumor necrosis factor alpha Penicillamine |
Add to Reading List |
DSU sequential TNFs report | BIOLOGICS IN THE PRACTICE OF LAW LINDSAY KELLY* Biologics have come to occupy an increasingly important role in the medical industry, accounting for well over $200 billion in worldwide sales inNot surprisingly, biDocID: 1rrNB - View Document |
| Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2DocID: 1rmwo - View Document |
| EAP Reimbursement Criteria for Frequently Requested DrugsDocID: 1rhhE - View Document |
| UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting Data presentations include: Positive results from Period 1 of the C-EARLY™ Phase 3 study of CIMZIA® (certolDocID: 1rakB - View Document |
| TABLE OF CONTENTS INTRODUCTION 2DocID: 1qY7G - View Document |